Clinical Research Directory

Evaluation of Crisaborole 2% Versus Tacrolimus 0.1% Each Combined With Excimer Light in the Treatment of Stable Non-segmental Facial Vitiligo: a Prospective Randomized Controlled Study.

The goal of this clinical trial is to learn if topical application of crisaborole 2% ointment can treat stable patches of facial vitiligo in pediatrics and adult patients of both genders. It will also learn about the safety of crisaborole 2% ointment. The main questions it aims to answer is: * Does crisaborole 2% ointment work effectively in stable localized facial vitiligo in pediatrics and adults? * is crisaborole 2% ointment well tolerated in stable localized facial vitiligo in pediatrics and adults? * Is crisaborole 2% ointment comparable to tacrolimus 0.1% ointment in terms of efficacy and safety in stable localized facial vitiligo in pediatrics and adults? Researchers will compare crisaborole 2% ointment to tacrolimus 0.1% ointment to see if crisaborole works as effective and is as well-tolerated. Participants will: * apply topical crisaborole 2% ointment or tacrolimus 0.1% ointment twice daily for 6 months (or until complete repigmentation, whichever earlier) to patches of stable facial vitiligo. * Visit the clinic twice every week for Excimer light sessions, checkups, and photography. * Keep a diary of their symptoms.

Adipose-derived Stem Cells Combined With Excimer Light in the Treatment of Stable Vitiligo

This study aimed to assess the efficacy and safety of intradermal injection of adipose-derived stem cells, alone and combined with excimer light in treatment of stable vitiligo.

Induced Pluripotent Stem Cell Derived Exosomes Nasal Drops for the Treatment of Stable Vitiligo

Evaluate the efficacy of induced pluripotent stem cell-derived exosomes (iPSC-Exos) for the treatment of stable vitiligo